Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EPS (Basic) (2018 - 2025)

10x Genomics' EPS (Basic) history spans 8 years, with the latest figure at -$0.13 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 68.29% year-over-year to -$0.13; the TTM value through Dec 2025 reached -$0.35, up 76.97%, while the annual FY2025 figure was -$0.35, 76.97% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.13 at 10x Genomics, up from -$0.22 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.28 in Q2 2025 and bottomed at -$0.79 in Q3 2023.
  • The 5-year median for EPS (Basic) is -$0.31 (2024), against an average of -$0.3.
  • The largest annual shift saw EPS (Basic) tumbled 470.0% in 2022 before it surged 187.5% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.17 in 2021, then grew by 11.76% to -$0.15 in 2022, then crashed by 173.33% to -$0.41 in 2023, then grew by 0.0% to -$0.41 in 2024, then soared by 68.29% to -$0.13 in 2025.
  • Per Business Quant, the three most recent readings for TXG's EPS (Basic) are -$0.13 (Q4 2025), -$0.22 (Q3 2025), and $0.28 (Q2 2025).